|Bid||4.12 x 100|
|Ask||6.18 x 100|
|Day's Range||5.89 - 6.15|
|52 Week Range||1.53 - 8.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2017 - May 1, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.50|
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the following presentations by
One of the biggest biotech conferences of the year is around the corner. The 59th annual meeting of the American Society of Hematology, or ASH, is Dec. 9-12 in Atlanta. It's likely to serve as a make-or-break ...
Cancer drug developer ImmunoGen posted sharply lower profits and revenues than analysts were expecting. The stock is taking a beating as a result.
ImmunoGen Inc (NASDAQ:IMGN), a USD$653.50M small-cap, operates in the healthcare industry, which faces demand for new drug development to meet new or persistent chronic illnesses, and ongoing need for biotechRead More...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 61 cents. Losses, adjusted for non-recurring costs, were 37 cents per share. The results did not meet Wall Street expectations. ...
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that three abstracts highlighting two of the Company’s experimental ADC therapies, IMGN632 and IMGN779, have been accepted for presentations at the upcoming American Society of Hematology Annual Meeting to be held December 9-12, 2017, in San Diego.
NEW YORK, Oct. 30, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dollar ...
In this article, I will take a quick look at ImmunoGen Inc’s (NASDAQ:IMGN) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure has been foundRead More...
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the U.S. Food and Drug Administration has completed the safety review of its investigational new drug application for IMGN632 in patients with CD123-positive hematological malignancies, including acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm .
ImmunoGen, Inc. today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock, including 2,175,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $6.50 per share.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for ImmunoGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Immunogen Inc. priced its secondary offering below the price of the close of shares on Friday, according to a filing with the Securities and Exchange Commission. The biotech company priced 14.5 million ...
ImmunoGen, Inc. today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price of $6.50 per share, before underwriting discounts.